Eurazeo, ADM in €60m round for M2I

The other investors in the round include family offices Téthys Invest and Creadev, and the France 2i fund managed by Raise Impact.

ADM acquired a minority stake in the company, drawing equity from its Cibus fund. The vehicle held a final close on $450m in January 2019 and typically writes cheques of $4-7m for growth investments.

The fresh capital will be used to expand the company's range of products, commercialise in France and internationally, and expand the number of products approved worldwide.

Previous funding
In 2017, Idinvest Partners provided a €12m round of funding for M2I, marking a fourth investment from its Growth Fund II.

Company
Founded in 2012, M2I designs and manufactures complex molecules. The company specialises in pheromones to replace pesticides. Headquartered in Saint-Cloud, the company also operates a research laboratory in Lacq, a production plant in Salin de Giraud and its manufacturing centre in Parnac. It employs 150 people.

People
ADM Capital – Alastair Cooper (head of venture capital).
M2I Life Sciences – Philippe Guerret (president).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• healthcare
• France
• Eurazeo
• Venture